{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch\n",
    "from datasets import load_dataset\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "ms2=load_dataset(\"allenai/mslr2022\",\"ms2\")\n",
    "cochrane=load_dataset(\"allenai/mslr2022\",\"cochrane\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "cochrane_df=cochrane[\"train\"].to_pandas()\n",
    "ms2_df=ms2[\"train\"].to_pandas()\n",
    "all_datasets=[cochrane_df,ms2_df]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "ms2_df.drop(columns=['background','review_id','pmid'],inplace=True)\n",
    "cochrane_df.drop(columns=['review_id','pmid'],inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "train_df=pd.concat([ms2_df,cochrane_df],axis=0).reset_index(drop=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "from nltk import sent_tokenize\n",
    "def conc_text(tit,abst):\n",
    "    text=[]\n",
    "    assert len(tit)==len(abst)\n",
    "    for i in range(len(abst)):\n",
    "        if tit[i].endswith(\".\") or tit[i].endswith(\"!\") or tit[i].endswith(\"?\"):\n",
    "            text.append(tit[i]+\" \"+abst[i])\n",
    "        else : text.append(tit[i]+\". \"+abst[i])\n",
    "    return \"<doc-sep>\".join(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "train_df[\"text\"]=train_df.apply(lambda row: conc_text(row['title'],row['abstract']),axis=1)\n",
    "train_df[\"text\"]=train_df[\"text\"].astype(str)\n",
    "train_df[\"target\"]=train_df[\"target\"].astype(str)\n",
    "train_df.drop(columns=['title','abstract'],inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "target    Conclusions SC therapy is effective for PAH in...\n",
       "text      Improved Cell Survival and Paracrine Capacity ...\n",
       "Name: 0, dtype: object"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train_df.loc[0]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Train the tokenizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "from collections import Counter\n",
    "vocab_freq=Counter()\n",
    "src_lens=[]\n",
    "tgt_lens=[]\n",
    "for index,row in train_df.iterrows():\n",
    "    v=row[\"text\"].split()\n",
    "    t=row[\"target\"].split()\n",
    "    src_lens.append(len(v))\n",
    "    tgt_lens.append(len(t))\n",
    "    vocab_freq.update(v)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "987567"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(vocab_freq)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Median 4323.0\n",
      "Mean 6177.204738015607\n",
      "Max 128566\n",
      "Min 6\n",
      "90-percentile 12767.700000000003\n"
     ]
    }
   ],
   "source": [
    "plt.boxplot(src_lens)\n",
    "plt.title(\"Length of src documents\")\n",
    "plt.show()\n",
    "print(\"Median\", np.median(src_lens))\n",
    "print(\"Mean\",np.mean(src_lens))\n",
    "print(\"Max\",np.max(src_lens))\n",
    "print(\"Min\",np.min(src_lens))\n",
    "n=90\n",
    "print(f\"{n}-percentile\",np.percentile(src_lens,n))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Median 52.0\n",
      "Mean 62.63952062430323\n",
      "Max 484\n",
      "Min 2\n",
      "90-percentile 116.0\n"
     ]
    }
   ],
   "source": [
    "plt.boxplot(tgt_lens)\n",
    "plt.title(\"Length of tgt documents\")\n",
    "plt.show()\n",
    "print(\"Median\", np.median(tgt_lens))\n",
    "print(\"Mean\",np.mean(tgt_lens))\n",
    "print(\"Max\",np.max(tgt_lens))\n",
    "print(\"Min\",np.min(tgt_lens))\n",
    "n=90\n",
    "print(f\"{n}-percentile\",np.percentile(tgt_lens,n))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "from transformers import AutoTokenizer\n",
    "from nltk import sent_tokenize\n",
    "old_tokenizer = AutoTokenizer.from_pretrained(\"allenai/PRIMERA\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_training_corpus(data):\n",
    "    return [data[i:i+100][\"text\"] for i in range(0,data.shape[0],100)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "vocab=vocab_freq.keys()\n",
    "training_corpus=get_training_corpus(train_df)\n",
    "tokenizer=old_tokenizer.train_new_from_iterator(training_corpus,70000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vocab size, 70000\n"
     ]
    }
   ],
   "source": [
    "print(\"Vocab size,\", len(tokenizer.vocab))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokenizer.pad_token_id"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('./primera-tokenizer\\\\tokenizer_config.json',\n",
       " './primera-tokenizer\\\\special_tokens_map.json',\n",
       " './primera-tokenizer\\\\vocab.json',\n",
       " './primera-tokenizer\\\\merges.txt',\n",
       " './primera-tokenizer\\\\added_tokens.json',\n",
       " './primera-tokenizer\\\\tokenizer.json')"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokenizer.save_pretrained(\"./primera-tokenizer\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokenizer.pad_token_id"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Token indices sequence length is longer than the specified maximum sequence length for this model (5420 > 4096). Running this sequence through the model will result in indexing errors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0, 17025, 13340, 7822, 282, 1562, 38553, 26079, 285, 10458, 43510, 2984, 29044, 13340, 18, 41064, 42925, 29044, 25338, 27926, 11028, 13873, 342, 9463, 14641, 8499, 19, 2178, 3702, 285, 2764, 1698, 6628, 20419, 6983, 2981, 301, 1673, 18, 29324, 304, 18903, 9467, 278, 283, 451, 342, 2209, 3319, 2361, 301, 22052, 304, 281, 283, 2503, 1157, 282, 16858, 2009, 285, 2764, 1673, 18, 29324, 820, 2720, 878, 2519, 6642, 288, 9390, 281, 314, 604, 283, 2519, 895, 285, 2608, 31496, 6983, 2221, 18, 8337, 19293, 301, 328, 65049, 18, 29324, 304, 321, 2764, 1673, 18, 29324, 342, 283, 451, 285, 22052, 278, 279, 7907, 1417, 288, 1934, 593, 1484, 37627, 39323, 381, 301, 40925, 3919, 3175, 22052, 281, 15538, 340, 335, 282, 997, 999, 309, 1319, 6847, 18, 33525, 3114, 301, 17380, 361, 304, 459, 406, 19, 21, 5040, 7866, 2608, 1673, 18, 8337, 19293, 301, 1673, 18, 29324, 361, 304, 380, 406, 19, 21, 5040, 7866, 328, 65049, 18, 8337, 19293, 301, 328, 65049, 18, 29324, 361, 304, 3524, 12334, 5034, 2530, 288, 1303, 406, 734, 27927, 281, 283, 4708, 3441, 2970, 1207, 301, 67704, 304, 281, 3860, 285, 11765, 11656, 281, 282, 7714, 7477, 21000, 285, 2209, 10189, 340, 960, 34, 281, 282, 2209, 12447, 3338, 347, 965, 278, 283, 328, 65049, 18, 22131, 361, 470, 604, 321, 1673, 18, 22131, 282, 17380, 543, 301, 658, 272, 642, 387, 19, 890, 304, 288, 1303, 324, 593, 27927, 281, 283, 1139, 285, 745, 40507, 19293, 278, 283, 19043, 347, 1212, 605, 965, 278, 283, 328, 65049, 18, 22131, 361, 562, 278, 283, 1673, 18, 22131, 361, 301, 658, 272, 642, 387, 19, 712, 304, 288, 1303, 406, 734, 27927, 281, 13392, 1673, 18, 29324, 340, 12926, 2137, 328, 65049, 18, 29324, 340, 525, 1135, 745, 40507, 278, 10021, 2209, 10189, 735, 607, 1035, 8168, 5122, 16858, 288, 481, 1296, 281, 2064, 25616, 285, 328, 65049, 18, 22131, 18, 282, 1673, 18, 22131, 18, 30604, 6464, 2959, 263, 7130, 23506, 2937, 2997, 288, 14550, 285, 1046, 1305, 1355, 1360, 1840, 1059, 287, 2959, 493, 37309, 1305, 519, 328, 65049, 18, 29324, 340, 26351, 3729, 278, 1424, 31496, 2104, 282, 3089, 16858, 281, 3822, 921, 9421, 7905, 6718, 288, 719, 5178, 493, 1180, 2221, 1157, 282, 23506, 2937, 2997, 285, 328, 65049, 18, 29324, 2387, 1581, 2519, 895, 562, 1673, 18, 29324, 278, 283, 451, 342, 22052, 5, 69357, 512, 18, 8337, 6983, 2981, 13666, 2209, 3319, 2361, 282, 17243, 2209, 3319, 12856, 278, 37627, 39323, 381, 18, 3175, 2209, 5514, 10380, 19, 3970, 719, 2403, 283, 754, 285, 13796, 18, 8337, 6983, 2981, 301, 28210, 5257, 304, 3702, 727, 378, 9741, 12856, 282, 2209, 2379, 1207, 278, 226, 37627, 39323, 381, 301, 40925, 3919, 3175, 2209, 5514, 10380, 288, 481, 283, 1004, 7295, 281, 1960, 2645, 35985, 18, 39475, 301, 1999, 304, 10380, 340, 335, 282, 997, 3261, 1355, 1432, 543, 301, 323, 446, 580, 20, 1618, 304, 505, 406, 28210, 5257, 1039, 543, 282, 1826, 579, 301, 60451, 81, 304, 288, 28210, 5257, 340, 1953, 1509, 283, 2789, 18178, 5034, 407, 7451, 281, 7866, 282, 8608, 2981, 281, 932, 281, 282, 263, 2221, 3338, 285, 7866, 31716, 20, 3543, 347, 2327, 309, 432, 4251, 288, 365, 611, 10636, 18, 42567, 2320, 28210, 5257, 340, 2194, 278, 283, 19043, 282, 16248, 1355, 5122, 18, 5018, 2981, 288, 481, 283, 1264, 7295, 281, 3573, 2645, 1999, 10380, 340, 335, 282, 997, 3261, 1355, 967, 543, 301, 323, 446, 1960, 20, 1618, 304, 505, 60451, 81, 281, 17380, 18, 3175, 2209, 3319, 2361, 301, 22052, 304, 281, 282, 22052, 1039, 321, 28210, 5257, 301, 28210, 5257, 304, 288, 2359, 734, 679, 18, 40925, 1926, 281, 283, 28210, 5257, 361, 816, 324, 5040, 7866, 28210, 5257, 3524, 283, 4626, 18178, 5034, 288, 3181, 309, 22052, 10380, 281, 762, 2209, 3319, 1207, 347, 1433, 278, 10380, 407, 324, 281, 357, 281, 282, 406, 734, 515, 28210, 5257, 18, 2145, 301, 1086, 19, 4359, 1153, 357, 19, 2078, 4385, 941, 955, 19, 4230, 1153, 357, 19, 3274, 4385, 459, 1709, 19, 2975, 1153, 357, 19, 3493, 4385, 941, 2089, 19, 2369, 1153, 357, 19, 2472, 4385, 459, 1585, 19, 4159, 1153, 357, 19, 3034, 4385, 941, 1810, 19, 3679, 1153, 406, 19, 2833, 4385, 281, 272, 642, 387, 19, 890, 304, 288, 29640, 281, 283, 4708, 1511, 11656, 1543, 301, 1810, 19, 23, 324, 1153, 453, 19, 3151, 354, 941, 2896, 19, 712, 1153, 324, 19, 3330, 354, 459, 2464, 19, 4361, 1153, 453, 19, 1289, 354, 941, 1807, 19, 2588, 1153, 357, 288, 2240, 354, 459, 2896, 19, 1289, 1153, 387, 19, 30, 354, 941, 1309, 19, 4410, 1153, 324, 19, 3865, 354, 281, 272, 642, 387, 19, 890, 281, 932, 304, 281, 1294, 285, 7477, 20, 22674, 5610, 281, 470, 1181, 470, 283, 7477, 20, 22674, 2475, 340, 605, 1200, 278, 22052, 10380, 407, 1046, 799, 2045, 1484, 28210, 5257, 18, 2145, 281, 470, 604, 321, 4828, 22052, 10380, 288, 481, 6820, 281, 28210, 5257, 905, 2380, 1813, 283, 2209, 10189, 281, 13666, 2209, 3319, 2361, 282, 17243, 2209, 3319, 12856, 5, 3271, 285, 1698, 6628, 20419, 6983, 2981, 378, 2099, 2209, 3319, 2361, 19, 365, 1343, 285, 283, 1398, 438, 347, 309, 2336, 283, 754, 285, 1698, 6628, 20419, 6983, 2221, 301, 35833, 304, 6948, 22, 385, 319, 378, 2241, 282, 1511, 5581, 278, 263, 22814, 1417, 285, 37627, 39323, 381, 301, 40925, 3919, 3175, 2209, 3319, 2361, 301, 22052, 304, 288, 365, 11348, 340, 335, 282, 997, 3261, 1355, 406, 543, 505, 579, 281, 22052, 226, 282, 226, 35833, 5293, 226, 543, 288, 27230, 1204, 278, 283, 2209, 3235, 7477, 281, 1757, 470, 283, 2209, 2379, 16398, 2475, 301, 7538, 304, 282, 3235, 2475, 301, 49399, 304, 340, 1257, 460, 50380, 282, 53393, 301, 450, 11, 42, 304, 11349, 281, 282, 283, 10909, 340, 3198, 460, 8836, 288, 2359, 734, 679, 18, 8971, 281, 2247, 840, 1956, 493, 8686, 5034, 2530, 285, 36823, 605, 8528, 283, 2209, 3235, 9741, 282, 5219, 1204, 4122, 460, 2209, 3319, 2361, 288, 365, 6345, 905, 432, 27869, 3524, 23506, 2937, 727, 5, 29667, 278, 358, 321, 845, 2209, 2361, 19, 1058, 519, 263, 5655, 2383, 8099, 19, 1407, 900, 12452, 1229, 278, 3121, 2692, 321, 845, 2209, 2361, 282, 309, 2336, 1305, 824, 321, 1157, 288, 1636, 7841, 321, 1077, 903, 951, 587, 18, 325, 288, 2246, 3024, 18, 3576, 606, 3532, 278, 283, 3931, 4375, 4978, 278, 283, 3728, 7841, 342, 283, 59135, 285, 3116, 9463, 8499, 5536, 460, 283, 3681, 4335, 281, 7765, 281, 282, 4536, 6023, 288, 3184, 935, 301, 14071, 304, 2692, 407, 606, 3532, 583, 324, 5989, 18690, 282, 2034, 5076, 12643, 282, 1490, 1509, 580, 7019, 11888, 288, 4711, 1303, 2159, 281, 2729, 285, 5219, 2031, 281, 2209, 847, 281, 282, 2022, 9981, 2031, 340, 3469, 278, 1296, 309, 1793, 378, 4034, 2031, 281, 1459, 2413, 281, 282, 1192, 18, 16292, 288, 935, 340, 1490, 342, 1157, 407, 473, 18, 1338, 3279, 288, 2724, 772, 365, 2803, 1477, 1157, 285, 1046, 358, 347, 357, 19, 29, 678, 301, 674, 354, 3805, 281, 324, 19, 30, 309, 406, 19, 28, 678, 304, 288, 16786, 1429, 18, 1236, 1157, 1037, 340, 470, 7722, 505, 407, 324, 582, 281, 3456, 354, 301, 3805, 281, 3545, 354, 309, 2076, 354, 304, 459, 407, 406, 678, 281, 1807, 354, 301, 3805, 281, 2896, 354, 309, 2571, 354, 304, 459, 282, 407, 479, 678, 281, 2170, 354, 301, 3805, 281, 955, 354, 309, 2495, 354, 304, 288, 17459, 824, 321, 2503, 1157, 1066, 263, 3623, 7274, 4335, 5833, 301, 11784, 304, 1822, 1948, 285, 2428, 380, 2376, 281, 3092, 285, 37194, 13488, 281, 3867, 762, 4708, 5149, 1207, 281, 3867, 762, 2209, 2379, 1207, 281, 1433, 1849, 1543, 281, 282, 1433, 36193, 2997, 342, 7217, 10612, 301, 36443, 304, 288, 6462, 677, 407, 4557, 380, 2244, 347, 525, 824, 321, 1157, 1541, 288, 1042, 7609, 347, 1369, 10010, 824, 321, 4708, 3441, 5219, 847, 282, 1084, 432, 7307, 460, 3715, 285, 279, 10552, 810, 967, 2031, 505, 762, 2209, 2379, 1207, 281, 762, 4708, 5149, 1207, 281, 282, 1849, 1543, 288, 9621, 279, 10552, 281, 2366, 4236, 2116, 292, 1077, 2592, 281, 1664, 432, 907, 470, 279, 6598, 278, 5491, 451, 2639, 282, 30707, 1459, 303, 4207, 5, 56365, 7584, 677, 342, 2209, 3319, 2361, 19, 1267, 31531, 15395, 27573, 1431, 479, 281, 279, 5841, 493, 9206, 5134, 16186, 40372, 34536, 281, 9518, 8306, 283, 16186, 40372, 34536, 18, 7258, 5348, 282, 3105, 5789, 285, 3235, 16034, 18, 25407, 2981, 281, 1617, 966, 278, 283, 2241, 288, 920, 481, 633, 1043, 18, 1054, 281, 594, 18, 1492, 438, 281, 314, 335, 282, 997, 999, 18317, 358, 321, 3157, 2209, 3319, 2361, 301, 1002, 7610, 380, 824, 321, 22137, 18, 15290, 817, 380, 321, 27409, 12888, 3436, 18, 1312, 18, 32174, 33149, 304, 309, 594, 380, 13356, 226, 301, 1001, 281, 1480, 281, 380, 2117, 619, 304, 5180, 967, 1929, 1100, 342, 621, 734, 288, 365, 845, 756, 2068, 347, 283, 1156, 519, 789, 309, 593, 621, 278, 283, 4993, 13639, 278, 1620, 2321, 288, 365, 1156, 278, 762, 2209, 18, 15582, 1207, 282, 9138, 1878, 8389, 301, 7076, 304, 1822, 1948, 282, 283, 1178, 285, 606, 7608, 340, 1035, 1075, 281, 735, 283, 438, 347, 525, 10904, 309, 635, 1229, 288, 935, 7403, 283, 621, 18, 1420, 335, 282, 634, 438, 1664, 6235, 263, 1263, 18, 788, 5036, 438, 288, 772, 365, 4993, 13639, 278, 1620, 2321, 906, 519, 789, 278, 658, 13356, 543, 459, 283, 762, 594, 18, 12181, 451, 727, 340, 2058, 294, 301, 773, 1152, 19, 21, 1184, 304, 281, 2686, 294, 301, 773, 1152, 19, 24, 1184, 304, 281, 282, 1309, 294, 301, 773, 1089, 19, 28, 1184, 304, 342, 1001, 281, 1480, 281, 282, 2117, 619, 285, 13356, 281, 932, 301, 348, 33, 21, 19, 850, 342, 658, 4843, 304, 288, 1463, 13356, 1883, 1200, 283, 762, 2209, 18, 15582, 1207, 301, 348, 34, 21, 19, 1545, 281, 348, 34, 21, 19, 712, 281, 282, 348, 33, 21, 19, 850, 281, 932, 304, 281, 1180, 283, 7076, 1822, 1948, 301, 348, 34, 21, 19, 3525, 281, 348, 33, 21, 19, 850, 281, 282, 348, 33, 21, 19, 850, 281, 932, 304, 281, 282, 340, 824, 321, 1968, 727, 1757, 470, 21726, 281, 10194, 281, 282, 5027, 288, 365, 1178, 285, 606, 7608, 936, 525, 2468, 605, 583, 283, 358, 1039, 321, 13356, 282, 966, 1039, 321, 594, 288, 2600, 283, 15564, 358, 7403, 884, 582, 285, 451, 321, 13356, 4091, 281, 283, 1247, 519, 789, 407, 884, 582, 278, 283, 4993, 13639, 278, 1620, 2321, 347, 3237, 294, 19, 1042, 31531, 2810, 944, 2997, 281, 7076, 1822, 1948, 281, 282, 10909, 278, 358, 321, 3157, 2209, 3319, 2361, 5, 54954, 58297, 282, 2532, 282, 1229, 278, 2209, 3319, 2361, 19, 1267, 6382, 4183, 342, 2209, 3319, 2361, 820, 1050, 11104, 378, 283, 3344, 285, 1745, 18, 788, 1177, 321, 944, 2997, 470, 283, 845, 756, 2068, 288, 719, 1075, 283, 895, 285, 64552, 281, 263, 1461, 5465, 18368, 18, 10853, 5990, 281, 810, 263, 845, 756, 2068, 285, 2532, 282, 1229, 278, 263, 1263, 18, 788, 494, 288, 920, 719, 335, 282, 997, 999, 358, 321, 3157, 2209, 3319, 2361, 309, 1319, 594, 2366, 1100, 281, 64552, 407, 263, 2366, 18, 4999, 1079, 285, 406, 619, 281, 380, 64552, 407, 263, 2366, 18, 4999, 1079, 285, 684, 619, 288, 21089, 757, 285, 1376, 380, 5269, 677, 342, 2209, 3319, 2361, 281, 1063, 562, 18368, 18, 10853, 10864, 281, 347, 6876, 407, 438, 4557, 288, 365, 845, 756, 2068, 347, 283, 799, 519, 283, 4525, 285, 451, 309, 283, 1004, 4310, 285, 263, 4407, 756, 2068, 285, 1466, 281, 5149, 19304, 8625, 281, 2241, 3702, 281, 4525, 285, 451, 321, 2126, 380, 4504, 58978, 281, 380, 7608, 285, 2209, 3319, 2361, 288, 772, 352, 832, 285, 4427, 358, 340, 335, 282, 997, 999, 309, 594, 281, 4427, 309, 283, 406, 18, 3855, 64552, 1079, 281, 282, 17570, 309, 283, 684, 18, 3855, 64552, 1079, 288, 365, 845, 756, 2068, 1701, 278, 2686, 19, 25, 354, 281, 2350, 19, 21, 354, 281, 282, 2034, 19, 25, 354, 285, 283, 358, 278, 1046, 543, 281, 932, 288, 365, 2215, 1294, 342, 283, 406, 18, 3855, 64552, 1079, 470, 604, 321, 594, 347, 387, 19, 3616, 301, 4315, 19, 26, 354, 1392, 1172, 752, 728, 797, 281, 387, 19, 4410, 309, 387, 19, 4238, 459, 348, 34, 21, 19, 712, 304, 281, 282, 283, 2215, 1294, 342, 283, 684, 18, 3855, 64552, 1079, 470, 604, 321, 594, 347, 387, 19, 4003, 301, 4315, 19, 26, 354, 728, 281, 387, 19, 3630, 309, 387, 19, 3686, 459, 348, 33, 21, 19, 850, 304, 288, 47853, 285, 2209, 3319, 2361, 347, 283, 1369, 3249, 845, 756, 18, 2279, 2913, 288, 365, 754, 285, 64552, 378, 633, 756, 2068, 347, 1211, 5758, 285, 1285, 283, 875, 347, 1341, 677, 342, 2209, 3319, 2361, 407, 789, 288, 5427, 1234, 682, 3563, 824, 321, 64552, 562, 321, 594, 340, 4901, 281, 33589, 281, 282, 5509, 288, 1042, 14161, 58297, 605, 1200, 2532, 282, 1229, 971, 358, 321, 2209, 3319, 2361, 278, 633, 2913, 18, 12729, 438, 288, 301, 9314, 460, 1931, 10048, 395, 19173, 459, 3866, 2853, 15707, 1596, 1651, 2593, 19, 2663, 1139, 281, 2631, 37615, 65078, 288, 304, 5, 7191, 18, 788, 1788, 285, 6983, 2981, 278, 37627, 39323, 381, 18, 3175, 2209, 3319, 2361, 19, 2347, 1591, 1068, 820, 2327, 493, 1698, 6628, 20419, 6983, 2981, 301, 36823, 304, 1084, 3971, 283, 2108, 285, 2209, 2379, 2361, 301, 22052, 304, 278, 283, 37627, 39323, 381, 301, 17380, 304, 1417, 278, 283, 1745, 3518, 288, 365, 1343, 285, 633, 438, 347, 309, 2024, 2336, 283, 1263, 18, 788, 754, 285, 36823, 378, 22052, 282, 309, 6080, 283, 6345, 285, 283, 5490, 754, 1617, 283, 2209, 3235, 12856, 282, 2221, 16858, 288, 22052, 1417, 347, 3413, 460, 4504, 2530, 285, 1309, 619, 20, 1707, 17380, 470, 2707, 438, 288, 18137, 281, 283, 11348, 340, 335, 282, 997, 3261, 1355, 967, 543, 301, 323, 446, 684, 278, 1107, 361, 304, 505, 579, 281, 22052, 361, 281, 282, 36823, 5293, 361, 288, 2557, 596, 515, 2530, 281, 59490, 282, 17055, 945, 2740, 283, 226, 17380, 18, 3175, 16997, 18, 14703, 5610, 278, 8391, 10189, 347, 1200, 301, 348, 642, 387, 19, 890, 304, 459, 283, 2475, 285, 8219, 18089, 278, 2241, 3089, 347, 960, 301, 348, 642, 387, 19, 890, 304, 281, 282, 283, 49437, 2221, 15491, 5281, 1357, 278, 2209, 2379, 16034, 1967, 2981, 347, 1433, 301, 348, 642, 387, 19, 890, 304, 288, 9501, 25689, 1083, 493, 283, 2981, 820, 283, 3168, 309, 18198, 583, 12999, 25596, 282, 1927, 282, 3235, 5122, 3105, 1927, 288, 2557, 596, 515, 2126, 2530, 281, 36823, 1664, 605, 751, 2209, 847, 460, 16867, 283, 3441, 12856, 282, 283, 754, 285, 2221, 16858, 5, 12245, 282, 895, 285, 6207, 5122, 19767, 2981, 3702, 278, 914, 321, 7610, 2209, 3319, 2361, 31, 1831, 18, 3259, 2555, 438, 19, 9811, 956, 1639, 493, 3702, 285, 31752, 17051, 37627, 39323, 381, 18, 3175, 2209, 2361, 278, 10380, 282, 18096, 288, 481, 1296, 281, 2247, 1591, 1068, 3541, 493, 6207, 16831, 3702, 347, 4205, 281, 2415, 281, 282, 3017, 820, 2843, 727, 378, 944, 2997, 282, 2209, 10909, 278, 1735, 321, 62680, 288, 4591, 281, 314, 5661, 493, 3702, 285, 31752, 2141, 751, 944, 2997, 282, 2209, 10909, 278, 914, 321, 62680, 288, 10721, 914, 321, 62680, 816, 2126, 2331, 285, 6207, 31752, 288, 365, 4708, 18, 7638, 1511, 7969, 282, 473, 18, 13380, 913, 340, 1230, 407, 789, 282, 407, 283, 799, 285, 621, 4793, 515, 2221, 2331, 288, 1303, 283, 799, 285, 621, 4793, 281, 294, 6124, 1433, 460, 473, 19, 25, 4385, 519, 2248, 19, 24, 773, 1108, 934, 19, 21, 309, 3299, 19, 30, 773, 1108, 934, 19, 24, 4385, 301, 272, 446, 387, 19, 7783, 304, 288, 23734, 1433, 460, 3453, 934, 354, 519, 54242, 773, 1108, 32119, 309, 39719, 773, 1108, 26068, 34218, 274, 20, 6858, 13, 26, 304, 301, 272, 446, 387, 19, 10926, 304, 288, 2052, 906, 519, 406, 19, 3630, 773, 1108, 387, 19, 3665, 309, 406, 19, 3117, 773, 1108, 387, 19, 4266, 602, 20, 673, 301, 272, 446, 387, 19, 10895, 304, 288, 365, 473, 18, 13380, 906, 460, 2464, 294, 519, 23715, 773, 1108, 3906, 309, 21600, 773, 1108, 3443, 294, 301, 272, 446, 387, 19, 7768, 304, 288, 11784, 1822, 1948, 1035, 1180, 288, 929, 340, 599, 1504, 1304, 1234, 321, 2221, 2331, 288, 365, 1945, 2555, 438, 3541, 493, 2126, 2331, 285, 6207, 31752, 347, 4205, 281, 2415, 281, 282, 824, 321, 455, 2080, 278, 944, 2997, 281, 11784, 1822, 1948, 281, 282, 2209, 10909, 278, 914, 321, 62680, 288, 34906, 285, 1046, 840, 278, 263, 335, 282, 634, 767, 494, 655, 5362, 5, 35729, 25126, 342, 1504, 2209, 2361, 19, 1267, 32900, 1068, 3541, 493, 22218, 25126, 281, 263, 3133, 4608, 285, 21595, 281, 4269, 5139, 2209, 23529, 282, 2810, 10909, 282, 944, 2997, 278, 358, 321, 2209, 2361, 288, 920, 719, 604, 3004, 1100, 26028, 285, 357, 19, 26, 380, 479, 19, 21, 3511, 285, 25126, 301, 1620, 380, 3979, 1929, 426, 1158, 459, 1477, 5269, 1079, 281, 1053, 3511, 426, 1158, 304, 321, 9175, 285, 594, 288, 226, 352, 832, 285, 14657, 358, 321, 2251, 6287, 285, 1504, 2209, 3319, 2361, 282, 1231, 8896, 2209, 2361, 301, 3623, 7274, 4335, 5833, 752, 11784, 797, 1822, 1948, 2428, 380, 2376, 304, 340, 1066, 288, 365, 845, 756, 2068, 347, 1261, 1783, 281, 515, 593, 621, 281, 283, 11784, 1948, 282, 4993, 13639, 278, 1620, 2321, 340, 1180, 460, 407, 1597, 884, 1948, 282, 407, 1597, 684, 1184, 281, 932, 281, 278, 283, 4393, 285, 606, 6662, 2166, 309, 9623, 1870, 282, 1466, 288, 772, 365, 1772, 606, 756, 2068, 347, 1261, 460, 1167, 19, 29, 1184, 285, 283, 358, 1341, 25126, 281, 470, 604, 321, 453, 19, 30, 1184, 285, 283, 358, 1341, 594, 301, 348, 34, 21, 19, 5403, 304, 288, 929, 340, 2425, 278, 283, 4993, 13639, 278, 1620, 2321, 285, 1810, 19, 25, 294, 278, 283, 25126, 361, 470, 263, 3592, 301, 348, 34, 21, 19, 3974, 304, 282, 285, 3204, 19, 29, 294, 278, 283, 2854, 285, 358, 321, 845, 2209, 2361, 288, 3164, 281, 453, 19, 21, 1184, 285, 358, 278, 283, 25126, 361, 301, 1617, 884, 648, 4084, 304, 282, 1152, 19, 28, 1184, 285, 966, 278, 283, 594, 361, 301, 1617, 1432, 648, 4084, 304, 936, 525, 2224, 283, 438, 301, 348, 34, 21, 19, 10626, 304, 459, 283, 1369, 1675, 5512, 342, 4612, 347, 606, 6662, 288, 2431, 604, 321, 3771, 18, 1693, 1916, 281, 5219, 1916, 340, 605, 1180, 407, 621, 734, 1292, 1257, 515, 25126, 9175, 301, 348, 33, 21, 19, 850, 304, 281, 340, 7273, 5208, 1292, 1257, 1169, 25126, 9175, 281, 282, 340, 605, 5506, 278, 283, 594, 361, 288, 2636, 455, 2843, 727, 285, 25126, 451, 1066, 279, 1247, 278, 283, 11784, 1948, 301, 348, 34, 21, 19, 1462, 304, 281, 7086, 301, 348, 34, 21, 19, 7783, 304, 281, 282, 1023, 285, 1192, 301, 348, 34, 21, 19, 10382, 304, 288, 14381, 12936, 1701, 321, 1134, 1935, 278, 283, 706, 543, 735, 347, 682, 3563, 4816, 470, 3226, 278, 283, 25126, 361, 281, 2681, 633, 1304, 754, 347, 525, 824, 321, 606, 6662, 288, 1042, 21721, 25126, 472, 279, 1030, 677, 342, 358, 321, 1504, 2209, 2361, 5, 56365, 2995, 2209, 3235, 2354, 278, 1429, 3441, 16376, 19, 1267, 3933, 2209, 3235, 2354, 301, 23734, 304, 905, 432, 263, 640, 1927, 342, 1424, 282, 3613, 1229, 278, 761, 5190, 268, 14877, 282, 43009, 293, 3791, 358, 288, 4717, 281, 23734, 905, 1191, 1263, 515, 283, 43009, 293, 3791, 288, 9037, 2209, 38355, 1757, 470, 27573, 479, 5015, 1084, 1725, 23734, 278, 358, 321, 1429, 3441, 16376, 3856, 25822, 288, 920, 1619, 772, 792, 347, 263, 1077, 903, 951, 281, 2437, 438, 288, 935, 321, 1429, 3441, 16376, 648, 820, 263, 23734, 1543, 965, 562, 357, 19, 26, 37001, 3127, 7828, 226, 165, 242, 100, 301, 537, 58, 304, 340, 1728, 288, 226, 7861, 7969, 347, 1230, 1169, 282, 515, 1926, 285, 13356, 278, 658, 358, 288, 1486, 283, 43009, 293, 3791, 281, 263, 226, 1620, 6904, 5970, 913, 226, 301, 473, 13757, 304, 347, 1035, 1230, 288, 352, 832, 285, 2374, 358, 340, 1728, 288, 23734, 347, 605, 1433, 278, 1107, 2274, 285, 1429, 3441, 16376, 515, 13356, 1926, 505, 519, 453, 19, 24, 963, 22, 19, 26, 60, 58, 309, 357, 19, 22, 963, 21, 19, 27, 60, 58, 301, 272, 33, 21, 19, 712, 304, 278, 358, 1169, 263, 5190, 11149, 14877, 281, 519, 406, 19, 23, 963, 21, 19, 26, 60, 58, 309, 324, 19, 27, 963, 21, 19, 27, 60, 58, 301, 272, 33, 21, 19, 850, 304, 278, 358, 515, 263, 5190, 11149, 14877, 281, 282, 519, 406, 19, 30, 963, 22, 19, 28, 60, 58, 309, 357, 19, 24, 963, 21, 19, 29, 60, 58, 301, 272, 33, 21, 19, 850, 304, 278, 358, 515, 43009, 293, 288, 481, 358, 515, 43009, 293, 281, 283, 473, 13757, 906, 519, 23918, 963, 3995, 294, 309, 24284, 963, 4088, 294, 301, 272, 33, 21, 19, 712, 304, 281, 282, 11784, 1822, 1948, 1180, 605, 301, 272, 33, 21, 19, 890, 304, 515, 13356, 1926, 288, 1347, 1487, 1968, 727, 340, 1211, 278, 1507, 358, 288, 1042, 31531, 1200, 23734, 278, 358, 321, 1429, 19616, 16376, 288, 31531, 906, 944, 2997, 282, 1180, 11784, 1822, 1948, 278, 358, 515, 263, 43009, 293, 3791, 288, 792, 21775, 493, 2209, 14754, 472, 263, 2009, 2519, 2131, 278, 2251, 358, 321, 3867, 23734, 321, 1429, 19616, 16376, 288, 5356, 18, 788, 606, 3489, 13604, 2024, 438, 5, 41258, 45468, 677, 342, 2209, 3319, 2361, 19, 2652, 365, 2401, 285, 633, 438, 347, 309, 2556, 283, 895, 282, 1414, 285, 1432, 1883, 285, 54310, 281, 279, 1376, 18368, 1431, 352, 3537, 18, 18072, 5990, 281, 278, 358, 321, 2209, 3319, 2361, 301, 22052, 304, 288, 1267, 9463, 3319, 2361, 472, 263, 1192, 18, 12275, 282, 4486, 817, 321, 2720, 451, 7044, 288, 52054, 472, 263, 31815, 282, 16034, 1967, 2221, 36797, 493, 13417, 263, 5062, 2436, 278, 283, 10885, 282, 2108, 285, 22052, 288, 920, 481, 633, 1043, 18, 1054, 281, 1079, 18, 16551, 438, 281, 2951, 358, 321, 7610, 22052, 380, 22052, 824, 321, 8219, 3235, 817, 281, 12558, 93, 19710, 757, 281, 380, 2608, 7944, 4064, 1582, 340, 335, 282, 634, 309, 1319, 324, 281, 357, 19, 26, 281, 479, 281, 380, 684, 619, 285, 54310, 2366, 1100, 342, 621, 734, 1490, 460, 621, 734, 285, 1831, 18, 3259, 54310, 288, 365, 845, 756, 2068, 347, 279, 1247, 519, 789, 278, 473, 18, 673, 5970, 4993, 301, 473, 13380, 304, 459, 2007, 756, 2045, 1066, 17568, 7086, 1543, 281, 9138, 1878, 8389, 301, 7076, 304, 1822, 1948, 281, 263, 5091, 3500, 1390, 281, 282, 5253, 10909, 288, 772, 1303, 621, 734, 281, 54310, 906, 473, 13380, 301, 773, 1810, 19, 22, 294, 281, 272, 642, 387, 19, 1936, 304, 321, 1134, 282, 1458, 455, 2425, 342, 1107, 1079, 361, 301, 1630, 281, 773, 2089, 19, 30, 309, 773, 2350, 19, 22, 294, 304, 288, 9346, 340, 1035, 1211, 278, 17568, 7086, 1543, 281, 7076, 1822, 1948, 281, 5091, 3500, 1390, 281, 762, 2209, 3319, 1207, 301, 536, 26, 19, 23, 1176, 2751, 281, 272, 642, 387, 19, 1936, 304, 281, 282, 1849, 1543, 301, 773, 387, 19, 3251, 339, 20, 673, 20, 82, 23, 281, 272, 642, 387, 19, 18816, 304, 288, 5427, 1234, 340, 2260, 282, 10272, 309, 1079, 281, 1617, 283, 1178, 285, 3867, 1488, 9056, 2107, 1381, 406, 1929, 283, 3416, 4265, 285, 1826, 301, 406, 19, 22, 354, 304, 288, 1042, 12280, 45468, 3830, 309, 751, 944, 2997, 281, 1047, 281, 282, 10909, 278, 358, 321, 22052, 288, 365, 1178, 282, 1981, 285, 3044, 5841, 6170, 2552, 309, 432, 598, 5, 47277, 18054, 6983, 2221, 1648, 285, 3235, 12856, 278, 591, 2827, 18, 3175, 2209, 2361, 1509, 263, 23506, 2937, 6345, 19, 10872, 9463, 3319, 2361, 301, 22052, 304, 472, 7307, 460, 1822, 282, 9741, 1204, 278, 283, 2209, 32333, 281, 282, 4403, 283, 1103, 451, 493, 2960, 455, 7817, 281, 283, 4832, 285, 358, 321, 2144, 7012, 3856, 10600, 2503, 288, 481, 283, 1398, 438, 281, 314, 2403, 283, 1424, 754, 285, 1698, 6628, 20419, 6983, 2981, 301, 36823, 304, 378, 2099, 591, 921, 2827, 18, 3175, 22052, 1417, 10380, 282, 5504, 283, 6345, 288, 36823, 340, 6201, 281, 14201, 519, 1698, 6628, 285, 35985, 18, 39475, 301, 1999, 304, 22814, 288, 365, 7907, 1417, 285, 22052, 347, 10727, 460, 1860, 2200, 309, 5928, 263, 2789, 18, 1312, 18, 16492, 14877, 288, 5609, 283, 2902, 20520, 285, 283, 22052, 1417, 281, 10380, 340, 335, 282, 997, 999, 309, 967, 543, 301, 323, 34, 2233, 278, 1107, 361, 304, 505, 4021, 361, 301, 579, 304, 281, 22052, 361, 281, 282, 35833, 361, 301, 816, 263, 8686, 5034, 2530, 285, 324, 536, 479, 5040, 684, 13, 27, 304, 36823, 304, 288, 2359, 734, 515, 283, 1926, 281, 36823, 605, 1200, 283, 3235, 12856, 281, 1180, 283, 5219, 956, 281, 282, 21965, 283, 4708, 19616, 1033, 1294, 309, 2789, 3441, 1361, 21812, 1033, 301, 11765, 20, 16615, 16, 56, 304, 301, 348, 33, 21, 19, 890, 304, 288, 20008, 18, 2845, 8463, 19939, 18, 41800, 8869, 5471, 301, 3821, 18, 14531, 304, 282, 17055, 945, 840, 2740, 493, 283, 4141, 1305, 1757, 470, 6108, 18, 22, 8737, 301, 3001, 18, 22, 8737, 304, 281, 3001, 18, 27, 281, 282, 2824, 7092, 1927, 18, 7103, 301, 6640, 18, 7103, 304, 340, 1200, 301, 348, 33, 21, 19, 890, 304, 459, 283, 4222, 285, 12628, 15959, 588, 59498, 18, 30, 301, 15118, 18, 30, 304, 347, 960, 301, 348, 33, 21, 19, 890, 304, 459, 3235, 5122, 3105, 1927, 301, 10319, 304, 347, 965, 278, 35833, 361, 562, 966, 278, 22052, 361, 301, 348, 33, 21, 19, 890, 304, 288, 770, 23187, 5034, 2530, 285, 36823, 342, 357, 734, 281, 605, 1180, 283, 2241, 282, 1511, 2228, 4122, 460, 2789, 18, 1312, 18, 16492, 14877, 18, 3175, 22052, 459, 1433, 2209, 3235, 12856, 282, 4141, 459, 282, 4068, 18555, 5, 19833, 4504, 2331, 285, 35571, 17, 263, 21595, 4608, 17, 278, 358, 321, 2209, 3319, 2361, 31, 263, 1043, 18, 1054, 17, 1045, 17, 594, 18, 1492, 494, 19, 9463, 3319, 2361, 472, 263, 1192, 18, 12275, 817, 342, 1011, 2490, 2126, 21595, 1061, 6825, 309, 432, 1030, 288, 1391, 281, 633, 451, 6697, 263, 8721, 3356, 3012, 2818, 321, 283, 824, 640, 285, 3226, 1738, 1757, 470, 4588, 281, 6197, 281, 380, 32049, 288, 322, 33515, 281, 263, 3133, 21595, 4608, 281, 1084, 432, 1953, 460, 263, 2490, 4504, 2331, 281, 14912, 1046, 4020, 288, 719, 1374, 263, 621, 18, 1420, 281, 1043, 18, 1054, 281, 594, 18, 1492, 2437, 494, 278, 25667, 358, 321, 2209, 3319, 2361, 281, 1002, 845, 380, 824, 321, 22137, 3089, 817, 380, 12888, 3436, 18, 1312, 18, 32174, 33149, 288, 226, 5072, 2997, 1180, 321, 35571, 282, 347, 5208, 321, 594, 459, 283, 583, 451, 361, 916, 278, 1477, 1620, 18, 4872, 3240, 4993, 347, 1167, 294, 301, 272, 446, 387, 19, 4734, 304, 288, 7753, 278, 944, 2997, 347, 1151, 278, 283, 45938, 358, 282, 347, 1079, 18, 1202, 281, 735, 1950, 285, 817, 10703, 288, 47998, 281, 35571, 605, 1180, 5804, 285, 7086, 281, 4173, 282, 1047, 285, 2209, 2361, 281, 282, 10909, 288, 365, 1369, 1675, 1968, 754, 8332, 309, 35571, 347, 2331, 3162, 675, 301, 3113, 354, 304, 5910, 309, 5567, 5060, 519, 283, 438, 278, 580, 354, 285, 358, 288, 3375, 358, 278, 283, 35571, 451, 361, 3846, 321, 279, 5261, 285, 4144, 5522, 288, 719, 3887, 493, 1231, 4504, 2331, 285, 35571, 472, 279, 1030, 451, 321, 279, 4977, 1414, 3326, 278, 358, 321, 2209, 3319, 2361, 5, 3309, 285, 283, 5465, 18368, 18, 10853, 5990, 19672, 278, 358, 321, 2209, 2361, 31, 263, 2075, 54493, 438, 19, 1267, 52054, 324, 281, 263, 12606, 9856, 31815, 282, 36797, 281, 3017, 432, 263, 3019, 285, 2209, 2361, 288, 719, 5174, 283, 895, 282, 1414, 285, 19672, 281, 263, 5465, 18368, 18, 10853, 5990, 493, 1084, 432, 3469, 5180, 281, 278, 358, 321, 1504, 2209, 2361, 288, 920, 481, 633, 1043, 18, 1054, 281, 594, 18, 1492, 438, 281, 1960, 358, 321, 2209, 2361, 301, 845, 380, 824, 321, 33875, 304, 340, 335, 282, 997, 999, 309, 19672, 301, 3442, 19, 26, 619, 3469, 2205, 1100, 342, 453, 734, 2533, 6746, 619, 2205, 1100, 304, 380, 594, 342, 263, 5251, 285, 621, 734, 288, 365, 845, 3058, 347, 1156, 278, 944, 2997, 288, 2860, 4551, 1066, 1204, 278, 5253, 21391, 281, 17568, 12518, 1543, 281, 7076, 1822, 1948, 281, 282, 4612, 2100, 309, 606, 7608, 288, 4143, 347, 460, 2908, 309, 415, 288, 4498, 481, 358, 1599, 19672, 281, 283, 4993, 13639, 278, 473, 896, 1180, 460, 2248, 294, 407, 621, 734, 604, 321, 789, 281, 2137, 1245, 12031, 460, 473, 294, 278, 966, 378, 594, 301, 916, 3575, 294, 752, 674, 354, 728, 621, 536, 11381, 797, 281, 272, 34, 21, 19, 10366, 304, 288, 365, 1247, 347, 3248, 342, 407, 1597, 1001, 734, 288, 365, 1849, 1543, 347, 324, 19, 21, 602, 896, 3926, 22, 304, 294, 3926, 23, 304, 301, 674, 354, 728, 387, 19, 27, 536, 324, 19, 25, 281, 272, 33, 21, 19, 1936, 304, 1151, 278, 358, 1599, 19672, 562, 278, 966, 1599, 594, 288, 226, 9463, 3235, 2354, 1433, 460, 14910, 34218, 274, 3120, 3926, 15805, 26, 304, 321, 19672, 281, 735, 906, 460, 14318, 34218, 274, 3120, 3926, 26, 304, 321, 594, 301, 916, 536, 36592, 752, 536, 26272, 309, 536, 27125, 797, 281, 272, 34, 21, 19, 9466, 304, 288, 935, 1599, 19672, 607, 263, 1200, 17568, 12518, 1543, 282, 279, 1180, 7076, 1822, 1948, 288, 1463, 967, 16969, 519, 606, 7608, 340, 278, 283, 594, 361, 301, 272, 34, 21, 19, 11847, 304, 288, 365, 1139, 282, 7788, 285, 1304, 1234, 936, 525, 2468, 583, 283, 706, 543, 288, 5165, 51283, 2425, 944, 2997, 282, 2810, 21391, 278, 358, 321, 2209, 2361, 281, 5047, 493, 18368, 1061, 279, 1952, 2436, 278, 2209, 2361, 5, 53366, 61566, 3749, 88, 640, 285, 3455, 3230, 342, 7907, 1068, 19, 1711, 10732, 8760, 274, 301, 27921, 304, 285, 2099, 7907, 1068, 655, 525, 5159, 1675, 1372, 281, 735, 7449, 285, 283, 16592, 285, 10235, 1757, 27921, 472, 23227, 2386, 288, 2431, 7907, 513, 1068, 2468, 519, 335, 282, 634, 606, 1177, 301, 2410, 304, 278, 3173, 5502, 281, 283, 9195, 342, 27921, 285, 606, 1177, 4750, 309, 432, 8786, 282, 15360, 342, 7907, 513, 1068, 288, 365, 6239, 8969, 2014, 263, 4630, 285, 20483, 301, 29595, 304, 3230, 309, 5537, 8179, 282, 4537, 13004, 278, 4161, 283, 1851, 7276, 1023, 285, 4438, 288, 352, 1134, 16379, 472, 6286, 278, 283, 5696, 285, 7907, 33018, 288, 1397, 719, 2387, 279, 29595, 3230, 342, 7907, 513, 1068, 301, 17128, 61566, 2197, 88, 29595, 3230, 304, 288, 792, 3230, 472, 1623, 378, 283, 6239, 29595, 3230, 282, 1061, 1050, 2300, 342, 5502, 285, 3455, 493, 3422, 263, 1895, 2436, 278, 7907, 513, 1068, 288, 900, 3709, 23727, 282, 13924, 281, 314, 18373, 32634, 4649, 309, 7047, 18007, 288, 1058, 365, 1542, 2293, 29595, 3230, 226, 342, 7907, 1068, 15915, 684, 27310, 288, 1532, 27310, 655, 1820, 309, 5338, 3455, 281, 1637, 3455, 281, 3975, 3455, 281, 10353, 3455, 281, 2985, 3455, 282, 1063, 12408, 288, 12491, 1046, 4221, 655, 278, 5933, 321, 283, 4221, 278, 283, 6239, 29595, 3230, 288, 4413, 285, 283, 9344, 583, 283, 706, 7685, 655, 2100, 309, 978, 278, 1238, 583, 4438, 282, 7907, 1068, 288, 4996, 26134, 278, 281, 380, 34288, 374, 321, 281, 1895, 5502, 285, 2099, 1238, 285, 7907, 1068, 604, 309, 606, 1068, 1035, 3422, 263, 2436, 288, 1644, 17128, 61566, 2197, 88, 29595, 3230, 472, 279, 8786, 5270, 285, 283, 6239, 29595, 3230, 288, 38723, 10480, 282, 3731, 285, 633, 3230, 1844, 7047, 282, 751, 5062, 9972, 285, 1413, 519, 7907, 1068, 288, 792, 905, 6882, 3709, 283, 6642, 285, 27686, 7907, 1788, 1355, 606, 1372, 282, 1191, 7449, 285, 283, 17093, 285, 2762, 283, 1851, 7276, 1023, 285, 7907, 1068, 2]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'<s>Improved Cell Survival and Paracrine Capacity of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells Promote Therapeutic Potential for Pulmonary Arterial Hypertension. Although transplantation of adult bone marrow mesenchymal stem cells ( BM-MSCs ) holds promise in the treatment for pulmonary arterial hypertension ( PAH ) , the poor survival and differentiation potential of adult BM-MSCs have limited their therapeutic efficiency . Here , we compared the therapeutic efficacy of human embryonic stem cell-derived MSCs ( hESC-MSCs ) with adult BM-MSCs for the treatment of PAH in an animal model . One week following monocrotaline (MCT)-induced PAH , mice were r and omly assigned to receive phosphate-buffered saline ( MCT group ) ; 3.0  106 human BM-derived MSCs ( BM-MSCs group ) or 3.0  106 hESC-derived MSCs ( hESC-MSCs group ) via tail vein injection . At 3 weeks posttransplantation , the right ventricular systolic pressure ( RVSP ) , degree of RV hypertrophy , and medial wall thickening of pulmonary arteries were lower= , and pulmonary capillary density was higher in the hESC-MSC group as compared with BM-MSC and MCT groups ( all p < 0.05 ) . At 1 week posttransplantation , the number of engrafted MSCs in the lungs was found significantly higher in the hESC-MSC group than in the BM-MSC group ( all p < 0.01 ) . At 3 weeks posttransplantation , implanted BM-MSCs were undetectable whereas hESC-MSCs were not only engrafted in injured pulmonary arteries but had also undergone endothelial differentiation . In addition , protein profiling of hESC-MSC- and BM-MSC-conditioned medium revealed a differential paracrine capacity . Classification of these factors into bioprocesses revealed that secreted factors from hESC-MSCs were preferentially involved in early embryonic development and tissue differentiation , especially blood vessel morphogenesis . We concluded that improved cell survival and paracrine capacity of hESC-MSCs provide better therapeutic efficacy than BM-MSCs in the treatment for PAH<doc-sep>Adipose-derived stem cells attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling in monocrotaline-induced pulmonary hypertensive rats. Abstract We investigated the effect of adipose-derived stem cells ( ADSCs ) transplantation effects on structural remodeling and pulmonary artery pressure in  monocrotaline (MCT)-induced pulmonary hypertensive rats . In the first experiment , 32 male Sprague-Dawley ( SD ) rats were r and omly divided into four groups ( n = 8/group ) : 3 ADSCs treated groups and normal control ( Ctrl ) . ADSCs were administered through the left jugular vein at 105 , 106 and 107 cells , respectively , and a cell density of 106cells/ml was shown to be optimal . The GFP-tagged ADSCs were identified in the lungs and differentiated into endothelial-like cells . In the second experiment , 96 male SD rats were r and omly divided into three groups ( n = 32/group ) : Ctrl , MCT-induced pulmonary arterial hypertension ( PAH ) , and PAH treated with ADSCs ( ADSCs ) . Two weeks post-MCT administration , the ADSCs group received 1  106 ADSCs via the external jugular vein . Compared to PAH rats , mean pulmonary arterial pressure was decreased in rats at 1 , 2 , and 3 weeks after ADSCs-treatment ( 18.63  2.15 mmHg versus 24.53  2.90 mmHg ; 23.07  2.84 mmHg versus 33.18  2.30 mmHg ; 22.98  2.34 mmHg versus 36.38  3.28 mmHg , p < 0.05 ) . Meanwhile , the right heart hypertrophy index ( 36.2 1  4.27 % versus 41.01  1.29 % ; 39.47  4.02 % versus 48.75  2 .13 % ; 41.02  0.9 % versus 50.52  1.49 % , p < 0.05 , respectively ) , ratio of wall/lumen thickness , as well as the wall/lumen area were significantly reduced in PAH rats at these time points following ADSCs-treatment , as compared with untreated PAH rats . In summary , ADSCs may colonize the pulmonary arteries , attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling<doc-sep>Effect of bone marrow mesenchymal stem cells on experimental pulmonary arterial hypertension. The aim of the present study was to investigate the effect of bone marrow mesenchymal stem cell ( BMSC ) transp1antation on lung and heart damage in a rat model of monocrotaline (MCT)-induced pulmonary arterial hypertension ( PAH ) . The animals were r and omly divided into 3 groups : control , PAH  and  BMSC implantation  groups . Structural changes in the pulmonary vascular wall , such as the pulmonary artery lumen area ( VA ) and vascular area ( TAA ) were measured by hematoxylin and eosin ( H&E ) staining , and the hemodynamics were detected by echocardiography . Two weeks post-operation , our results demonstrated that sublingual vein injection of BMSCs significantly attenuated the pulmonary vascular structural and hemodynamic changes caused by pulmonary arterial hypertension . The mechanism may be executed via paracrine effects<doc-sep>Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. OBJECTIVE To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival . DESIGN Registry with prospect i ve follow-up . SETTING Thirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart , Lung , and Blood Institute . PATIENTS Patients ( 194 ) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988 . MEASUREMENTS At diagnosis , measurements of hemodynamic variables , pulmonary function , and gas exchange variables were taken in addition to information on demographic variables , medical history , and life-style . Patients were followed for survival at 6-month intervals . MAIN RESULTS The estimated median survival of these patients was 2.8 years ( 95 % Cl , 1.9 to 3.7 years ) . Estimated single-year survival rates were as follows : at 1 year , 68 % ( Cl , 61 % to 75 % ) ; at 3 years , 48 % ( Cl , 41 % to 55 % ) ; and at 5 years , 34 % ( Cl , 24 % to 44 % ) . Variables associated with poor survival included a New York Heart Association ( NYHA ) functional class of III or IV , presence of Raynaud phenomenon , elevated mean right atrial pressure , elevated mean pulmonary artery pressure , decreased cardiac index , and decreased diffusing capacity for carbon monoxide ( DLCO ) . Drug therapy at entry or discharge was not associated with survival duration . CONCLUSIONS Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables : mean pulmonary artery pressure , mean right atrial pressure , and cardiac index . Such an equation , once vali date d prospect ively , could be used as an adjunct in planning treatment strategies and allocating medical re sources<doc-sep>Sildenafil citrate therapy for pulmonary arterial hypertension. BACKGROUND Sildenafil inhibits phosphodiesterase type 5 , an enzyme that metabolizes cyclic guanosine monophosphate , thereby enhancing the cyclic guanosine monophosphate-mediated relaxation and growth inhibition of vascular smooth-muscle cells , including those in the lung . METHODS In this double-blind , placebo-controlled study , we r and omly assigned 278 patients with symptomatic pulmonary arterial hypertension ( either idiopathic or associated with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts ) to placebo or sildenafil  ( 20 , 40 , or 80 mg ) orally three times daily for 12 weeks . The primary end point was the change from baseline to week 12 in the distance walked in six minutes . The change in mean pulmonary-artery pressure and World Health Organization ( WHO ) functional class and the incidence of clinical worsening were also assessed , but the study was not powered to assess mortality . Patients completing the 12-week r and omized study could enter a long-term extension study . RESULTS The distance walked in six minutes increased from baseline in all sildenafil groups ; the mean placebo-corrected treatment effects were 45 m ( + 13.0 percent ) , 46 m ( + 13.3 percent ) , and 50 m ( + 14.7 percent ) for 20 , 40 , and 80 mg of sildenafil , respectively ( P<0.001 for all comparisons ) . All sildenafil doses reduced the mean pulmonary-artery pressure ( P=0.04 , P=0.01 , and P<0.001 , respectively ) , improved the WHO functional class ( P=0.003 , P<0.001 , and P<0.001 , respectively ) , and were associated with side effects such as flushing , dyspepsia , and diarrhea . The incidence of clinical worsening did not differ significantly between the patients treated with sildenafil and those treated with placebo . Among the 222 patients completing one year of treatment with sildenafil monotherapy , the improvement from baseline at one year in the distance walked in six minutes was 51 m. CONCLUSIONS Sildenafil improves exercise capacity , WHO functional class , and hemodynamics in patients with symptomatic pulmonary arterial hypertension<doc-sep>Macitentan and morbidity and mortality in pulmonary arterial hypertension. BACKGROUND Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point . We assessed the efficacy of macitentan , a new dual endothelin-receptor antagonist , using a primary end point of morbidity and mortality in a long-term trial . METHODS We r and omly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily , macitentan at a once-daily dose of 3 mg , or macitentan at a once-daily dose of 10 mg . Stable use of oral or inhaled therapy for pulmonary arterial hypertension , other than endothelin-receptor antagonists , was allowed at study entry . The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death , atrial septostomy , lung transplantation , initiation of treatment with intravenous or subcutaneous prostanoids , or worsening of pulmonary arterial hypertension . RESULTS A total of 250 patients were r and omly assigned to placebo , 250 to the 3-mg macitentan dose , and 242 to the 10-mg macitentan dose . The primary end point occurred in 46.4 % , 38.0 % , and 31.4 % of the patients in these groups , respectively . The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 ( 97.5 % confidence interval [ CI ] , 0.52 to 0.96 ; P=0.01 ) , and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 ( 97.5 % CI , 0.39 to 0.76 ; P<0.001 ) . Worsening of pulmonary arterial hypertension was the most frequent primary end-point event . The effect of macitentan on this end point was observed regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline . Adverse events more frequently associated with macitentan than with placebo were headache , nasopharyngitis , and anemia . CONCLUSIONS Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study . ( Funded by Actelion Pharmaceuticals ; SERAPHIN Clinical Trials.gov number , NCT00660179 . )<doc-sep>Long-term research of stem cells in monocrotaline-induced pulmonary arterial hypertension. Our previous studies have shown that bone marrow mesenchymal stem cells ( BMSCs ) can inhibit the progression of pulmonary artery hypertension ( PAH ) in the monocrotaline ( MCT ) model in the short term . The aim of this study was to further investigate the long-term effect of BMSCs on PAH and to explore the mechanism of the protective effect including the pulmonary vascular remodeling and cell differentiation . PAH model was established by subcutaneous injection of 50 mg/kg MCT as previously study . Postoperatively , the animals were r and omly divided into three groups ( n = 10 in each group ) : control , PAH group , and BMSCs implantation group . Six months after injection , immunology and immunohistochemistry analysis indicated the  MCT-induced intima-media thickness in muscular arteries was reduced ( P < 0.05 ) ; the area of collagen fibers in lung tissue was lower ( P < 0.05 ) , and the proliferating cell nuclear antigen level in pulmonary artery smooth muscle cells was decreased ( P < 0.05 ) . Immunofluorescence showed that the cells have the ability to differentiate between von Willebr and factor and vascular endothelial growth factor . Six months after intravenous injection , BMSCs could significantly improve pulmonary function by inhibiting the ventricular remodeling and the effect of cell differentiation<doc-sep>Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Experimental data suggest that transplantation of EPCs attenuates monocrotaline-induced pulmonary hypertension in rats and dogs . In addition , our previous studies suggested that autologous EPC transplantation was feasible , safe , and might have beneficial effects on exercise capacity and pulmonary hemodynamics in adults with IPAH . Thus , we hypothesized that transplantation of EPCs would improve exercise capacity and pulmonary hemodynamics in children with IPAH . Thirteen children with IPAH received intravenous infusion of autologous EPCs . The right-sided heart catheterization and 6-MWD test were performed at baseline and at the time of 12 wk after cell infusion . At the time of 12 wk , mPAP decreased by 6.4 mmHg from 70.3 + /- 19.0 to 63.9 + /- 19.3 mmHg ( p = 0.015 ) . PVR decreased by approximately 19 % from 1118 + /- 537 to 906 + /- 377 dyn s/cm(5 ) ( p = 0.047 ) . CO increased from 3.39 + /- 0.79 to 3.85 + /- 0.42 L/min ( p = 0.048 ) . The 6-MWD increased by 39 m from 359 + /- 82 to 399 + /- 74 m ( p = 0.012 ) . NYHA functional class also improved . There were no severe adverse events with cell infusion . The small pilot study suggested that intravenous infusion of autologous EPCs was feasible , safe , and associated with significant improvements in exercise capacity , NYHA functional class , and pulmonary hemodynamics in children with IPAH . Confirmation of these results in a r and omized controlled trial are essential<doc-sep>Inhaled iloprost for severe pulmonary hypertension. BACKGROUND Uncontrolled studies suggested that aerosolized iloprost , a stable analogue of prostacyclin , causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension . METHODS We compared repeated daily inhalations of 2.5 or 5.0 microg of iloprost ( six or nine times per day ; median inhaled dose , 30 microg per day ) with inhalation of placebo .  A total of 203 patients with selected forms of severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension ( New York Heart Association [ NYHA ] functional class III or IV ) were included . The primary end point was met if , after week 12 , the NYHA class and distance walked in six minutes were improved by at least one class and at least 10 percent , respectively , in the absence of clinical deterioration according to predefined criteria and death . RESULTS The combined clinical end point was met by 16.8 percent of the patients receiving iloprost , as compared with 4.9 percent of the patients receiving placebo ( P=0.007 ) . There were increases in the distance walked in six minutes of 36.4 m in the iloprost group as a whole ( P=0.004 ) and of 58.8 m in the subgroup of patients with primary pulmonary hypertension . Overall , 4.0 percent of patients in the iloprost group ( including one who died ) and 13.7 percent of those in the placebo group ( including four who died ) did not complete the study ( P=0.024 ) ; the most common reason for withdrawal was clinical deterioration . As compared with base-line values , hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation ( P<0.001 ) , were largely unchanged when measured before iloprost inhalation , and were significantly worse in the placebo group . Further significant beneficial effects of iloprost treatment included an improvement in the NYHA class ( P=0.03 ) , dyspnea ( P=0.015 ) , and quality of life ( P=0.026 ) . Syncope occurred with similar frequency in the two groups but was more frequently rated as serious in the iloprost group , although this adverse effect was not associated with clinical deterioration . CONCLUSIONS Inhaled iloprost is an effective therapy for patients with severe pulmonary hypertension<doc-sep>Sildenafil reduces pulmonary vascular resistance in single ventricular physiology. BACKGROUND High pulmonary vascular resistance ( PVR ) may be a risk factor for early and late mortality in both Glen shunt and Fontan operation patients . Furthermore , PVR may increase long after the Fontan operation . Whether pulmonary vasodilators such as phosphodiesterase 5 inhibitors can decrease PVR in patients with single ventricular physiology remains undetermined . METHODS AND RESULTS This was a prospect i ve , multicenter study . Patients with single ventricular physiology who have a PVR index higher than 2.5 Wood units   ( WU ) were enrolled .  Cardiac catheterization was performed before and after administration of sildenafil in all patients . After the Fontan operation , a  six minute walk test  ( 6MWT ) was also performed . A total of 42 patients were enrolled . PVR was significantly decreased in each stage of single ventricular physiology after sildenafil administration : from 4.31.5WU to 2.10.6WU ( p<0.01 ) in patients before a Glenn shunt , from 3.20.5WU to 1.60.6WU ( p<0.001 ) in patients after a Glenn shunt , and from 3.91.7WU to 2.30.8WU ( p<0.001 ) in patients after Fontan . In patients after Fontan , the 6MWT increased from 41674 m to 48572 m ( p<0.01 ) , and NYHA functional class improved significantly ( p<0.05 ) after sildenafil administration . No major side effects were observed in any patients . CONCLUSIONS Sildenafil reduced PVR in patients with single ventricle physiology . Sildenafil increased exercise capacity and improved NYHA functional class in patients after a Fontan operation . This implies that pulmonary vasodilation is a potential therapeutic target in selected patients with elevated PVR with single ventricle physiology . Long-term clinical significance warrants further study<doc-sep>Ambrisentan therapy for pulmonary arterial hypertension. OBJECTIVES The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan , an oral endothelin type A receptor-selective antagonist , in patients with pulmonary arterial hypertension ( PAH ) . BACKGROUND Pulmonary arterial hypertension is a life-threatening and progressive disease with limited treatment options . Endothelin is a vasoconstrictor and smooth muscle cell mitogen that plays a critical role in the pathogenesis and progression of PAH . METHODS In this double-blind , dose-ranging study , 64 patients with idiopathic PAH or PAH associated with collagen vascular disease , anorexigen use , or human immunodeficiency virus infection were r and omized to receive 1 , 2.5 , 5 , or 10 mg of ambrisentan once daily for 12 weeks followed by 12 weeks of open-label ambrisentan . The primary end point was an improvement from baseline in 6-min walk distance ( 6MWD ) ; secondary end points included Borg dyspnea index , World Health Organization ( WHO ) functional class , a subject global assessment , and cardiopulmonary hemodynamics . RESULTS At 12 weeks , ambrisentan increased 6MWD ( + 36.1 m , p < 0.0001 ) with similar and statistically significant increases for each dose group ( range , + 33.9 to + 38.1 m ) . Improvements were also observed in Borg dyspnea index , WHO functional class , subject global assessment , mean pulmonary arterial pressure ( -5.2 mm Hg , p < 0.0001 ) , and cardiac index ( + 0.33 l/min/m2 , p < 0.0008 ) . Adverse events were mild and unrelated to dose , including the incidence of elevated serum aminotransferase concentrations > 3 times the upper limit of normal ( 3.1 % ) . CONCLUSIONS Ambrisentan appears to improve exercise capacity , symptoms , and hemodynamics in patients with PAH . The incidence and severity of liver enzyme abnormalities appear to be low<doc-sep>Mesenchymal stem cell prevention of vascular remodeling in high flow-induced pulmonary hypertension through a paracrine mechanism. UNLABELLED Pulmonary arterial hypertension ( PAH ) is characterized by functional and structural changes in the pulmonary vasculature , and despite the drug treatment that made significant progress , the prognosis of patients with advanced PH remains extremely poor . In the present study , we investigated the early effect of bone marrow mesenchymal stem cells ( BMSCs ) on experimental high blood flow-induced PAH model rats and discussed the mechanism . BMSCs were isolated , cultured from bone marrow of Sprague-Dawley ( SD ) rat . The animal model of PAH was created by surgical methods to produce a left-to-right shunt . Following the successful establishment of the PAH model , rats were r and omly assigned to three groups ( n=20 in each group ) : sham group ( control ) , PAH group , and BMSC group ( received a sublingual vein injection of 1 - 5  10(6 ) BMSCs ) . Two weeks after the administration , BMSCs significantly reduced the vascular remodeling , improved the hemodynamic data , and deceased the right ventricle weight ratio to left ventricular plus septal weight ( RV/LV+S ) ( P<0.05 ) . Real-time reverse transcription-polymerase chain reaction ( RT-PCR ) and immunohistochemistry analysis results indicated that the inflammation factors such as interleukin-1 ( IL-1 ) , IL-6 , and tumor necrosis factor- ( TNF- ) were reduced ( P<0.05 ) ; the expression of matrix metallo proteinase-9 ( MMP-9 ) was lower ( P<0.05 ) ; vascular endothelial growth factor ( VEGF ) was higher in BMSC group than those in PAH group ( P<0.05 ) . CONCLUSION Sublingual vein injection of BMSCs for 2 weeks , significantly improved the lung and heart injury caused by left-to-right shunt-induced PAH ; decreased pulmonary vascular remodeling and inflammation ; and enhanced angiogenesis<doc-sep>Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous prostacyclin has proven to be effective . However , this treatment requires a permanent central venous catheter with the associated risk of serious complications such as sepsis , thromboembolism , or syncope . Treprostinil , a stable prostacyclin analogue , can be administered by a continuous subcutaneous infusion , avoiding these risks . We conducted a 12-week , double-blind , placebo-controlled multicenter trial in 470 patients with pulmonary arterial hypertension , either primary or associated with connective tissue disease or congenital systemic-to-pulmonary shunts .  Exercise capacity improved with treprostinil and was unchanged with placebo ; the between treatment group difference in median six-minute walking distance was 16 m ( p = 0.006 ) . Improvement in exercise capacity was greater in the sicker patients and was dose-related , but independent of disease etiology . Concomitantly , treprostinil significantly improved indices of dyspnea , signs and symptoms of pulmonary hypertension , and hemodynamics . The most common side effect attributed to treprostinil was infusion site pain ( 85 % ) leading to premature discontinuation from the study in 8 % of patients . Three patients in the treprostinil treatment group presented with an episode of gastrointestinal hemorrhage . We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension<doc-sep>Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. BACKGROUND Endothelin 1 , a powerful endogenous vasoconstrictor and mitogen , might be a cause of pulmonary hypertension . We describe the efficacy and safety of bosentan , a dual endothelin-receptor antagonist that can be taken orally , in patients with severe pulmonary hypertension . METHODS In this double-blind , placebo-controlled study , 32 patients with pulmonary hypertension ( primary or associated with scleroderma ) were r and omly assigned to bosentan ( 62.5 mg taken twice daily for 4 weeks then 125 mg twice daily ) or placebo for a minimum of 12 weeks . The primary endpoint was change in exercise capacity . Secondary endpoints included changes in cardiopulmonary haemodynamics , Borg dyspnoea index , WHO functional class , and withdrawal due to clinical worsening . Analysis was by intention to treat . FINDINGS In patients given bosentan , the distance walked in 6 min improved by 70 m at 12 weeks compared with baseline , whereas it worsened by 6 m in those on placebo ( difference 76 m [ 95 % CI 12 - 139 ] , p=0.021 ) . The improvement was maintained for at least 20 weeks . The cardiac index was 1.0 L min(-1 ) m(-2 ) ( 95 % CI 0.6 - 1.4 , p<0.0001 ) greater in patients given bosentan than in those given placebo .  Pulmonary vascular resistance decreased by 223 dyn s cm(-)(5 ) with bosentan , but increased by 191 dyn s cm(-5 ) with placebo ( difference -415 [ -608 to -221 ] , p=0.0002 ) . Patients given bosentan had a reduced Borg dyspnoea index and an improved WHO functional class . All three withdrawals from clinical worsening were in the placebo group ( p=0.033 ) . The number and nature of adverse events did not differ between the two groups . INTERPRETATION Bosentan increases exercise capacity and improves haemodynamics in patients with pulmonary hypertension , suggesting that endothelin has an important role in pulmonary hypertension<doc-sep>SYRCLEs risk of bias tool for animal studies. Background Systematic Review s ( SRs ) of experimental animal studies are not yet common practice , but awareness of the merits of conducting such SRs is steadily increasing . As animal intervention studies differ from r and omized clinical trials ( RCT ) in many aspects , the methodology for SRs of clinical trials needs to be adapted and optimized for animal intervention studies . The Cochrane Collaboration developed a Risk of Bias ( RoB ) tool to establish consistency and avoid discrepancies in assessing the method ological quality of RCTs . A similar initiative is warranted in the field of animal experimentation . Methods We provide an RoB tool for animal intervention studies ( SYRCLE s RoB tool ) . This tool is based on the Cochrane RoB tool and has been adjusted for aspects of bias that play a specific role in animal intervention studies . To enhance transparency and applicability , we formulated signalling questions to facilitate judgment . Results The result ing RoB tool  for animal studies contains 10 entries . These entries are related to selection bias , performance bias , detection bias , attrition bias , reporting bias and other biases . Half these items are in agreement with the items in the Cochrane RoB tool . Most of the variations between the two tools are due to differences in design between RCTs and animal studies . Shortcomings in , or unfamiliarity with , specific aspects of experimental design of animal studies compared to clinical studies also play a role . Conclusions SYRCLE s RoB tool is an adapted version of the Cochrane RoB tool . Widespread adoption and implementation of this tool will facilitate and improve critical appraisal of evidence from animal studies . This may subsequently enhance the efficiency of translating animal research into clinical practice and increase awareness of the necessity of improving the method ological quality of animal studies</s>'"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text=train_df.loc[0].text\n",
    "ids=tokenizer.encode(text)\n",
    "print(ids)\n",
    "decoded_text=tokenizer.decode(ids)\n",
    "decoded_text"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
